


## NOV203: Figure Series

### Table of contents


Figure 2-1.1: Proteinuria (UPCR): Analysis of change from baseline (Full Analysis Set).....	2
Figure 2-4.1: Histology total activity score: Analysis of change from baseline (Full Analysis Set) .....	3
Figure 3-1.1: FACIT - Fatigue: Analysis of change from baseline (Full Analysis Set).....	4
Figure 3-2.1: EQ-5D VAS: Analysis of change from baseline (Full Analysis Set) .....	5
Figure 3-3.1: SF-36 PCS: Analysis of change from baseline (Full Analysis Set).....	6
Figure 3-4.1: SF-36 MCS: Analysis of change from baseline (Full Analysis Set) .....	7
Figure 3-5.1: PGIS: Analysis of change from baseline (Full Analysis Set) .....	8

**Figure 2-1.1: Proteinuria (UPCR): Analysis of change from baseline (Full Analysis Set)**




Subjects with Data		
Iptacopan	36	37
Placebo	35	36

**Figure 2-4.1: Histology total activity score: Analysis of change from baseline (Full Analysis Set)**




**Figure 3-1.1: FACIT - Fatigue: Analysis of change from baseline (Full Analysis Set)**




Subjects with Data					
		Day 14	Day 30	Day 90	Day 180
Iptacopan	34	34	34	34	36
Placebo	30	30	30	31	31

**Figure 3-2.1: EQ-5D VAS: Analysis of change from baseline (Full Analysis Set)**




Subjects with Data				
	Day 14	Day 30	Day 90	Day 180
Iptacopan	34	34	34	36
Placebo	30	30	31	31

**Figure 3-3.1: SF-36 PCS: Analysis of change from baseline (Full Analysis Set)**




Subjects with Data				
Iptacopan	34	34	34	35
Placebo	30	30	31	31

**Figure 3-4.1: SF-36 MCS: Analysis of change from baseline (Full Analysis Set)**



Subjects with Data				
Iptacopan	34	34	34	35
Placebo	30	30	31	31

**Figure 3-5.1: PGIS: Analysis of change from baseline (Full Analysis Set)**



Subjects with Data				
Iptacopan	34	34	34	36
Placebo	30	30	31	31